Literature DB >> 6336312

Localization of the human c-sis oncogene in Ph1-positive and Ph1-negative chronic myelocytic leukemia by in situ hybridization.

C R Bartram, A de Klein, A Hagemeijer, G Grosveld, N Heisterkamp, J Groffen.   

Abstract

Oncogenes are a group of evolutionary conserved cellular genes (c-onc) homologous to the transforming genes of oncogenic retroviruses (v-onc). Some of them are localized near the breakpoints of specific chromosomal aberrations occurring in various neoplasms, as for example the Philadelphia translocation, t(9;22)(q34;q11), in chronic myelocytic leukemia (CML). Recently, we localized the human c-abl oncogene to chromosome region 9q34 and demonstrated a translocation of this gene to the Philadelphia chromosome (Ph1,22q-) in various forms of Ph1-positive, but not Ph1-negative, chronic myelocytic leukemia (CML). Another human oncogene, c-sis, is located on chromosome 22 and was recently reported to be transferred to chromosome 9q+ in one CML patient. We have now studied 2 CML patients with classic and variant types of Ph1 translocation, one Ph1-negative case, and a healthy control using in situ hybridization of a c-sis probe to metaphase chromosomes. These studies show that c-sis: (1) is localized to region 22q12.3-q13.1, far away from the breakpoint region 22q11 in CML, (2) segregates with the translocated part of chromosome 22 to different chromosomes in Ph1-positive patients, and (3) remains on chromosome 22 in the Ph1-negative case. Therefore, these data give no support for an active role of the c-sis gene in the generation of CML. Thus, if either of these two oncogenes is involved in the development of Ph1-positive CML, c-abl appears to be the more important one.

Entities:  

Mesh:

Year:  1984        PMID: 6336312

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M R Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 2.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1991       Impact factor: 2.957

3.  Translocation of oncogene c-sis from chromosome 22 to chromosome 11 in a Ewing sarcoma-derived cell line.

Authors:  A G van Kessel; C Turc-Carel; A de Klein; G Grosveld; G Lenoir; D Bootsma
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

4.  Regulation of expression of the c-sis proto-oncogene.

Authors:  L Ratner
Journal:  Nucleic Acids Res       Date:  1989-06-12       Impact factor: 16.971

5.  Translocation of c-abl oncogene and PDGFB (c-sis) gene in a case of CML with 46,XY, t(22;22).

Authors:  G Gradl; H Tesch; G Schwieder; T Wagner; C Fonatsch
Journal:  Blut       Date:  1989-06

6.  Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis.

Authors:  I Nagaoka; B C Trapnell; R G Crystal
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 7.  Human chromosome 22.

Authors:  J C Kaplan; A Aurias; C Julier; M Prieur; M F Szajnert
Journal:  J Med Genet       Date:  1987-02       Impact factor: 6.318

8.  Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas.

Authors:  S H Bigner; H S Friedman; J A Biegel; C J Wikstrand; J Mark; R Gebhardt; L F Eng; D D Bigner
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

9.  An 8-kilobase abl RNA transcript in chronic myelogenous leukemia.

Authors:  R P Gale; E Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

10.  Isolation of two murine H1 histone genes and chromosomal mapping of the H1 gene complement.

Authors:  B Drabent; K Franke; C Bode; U Kosciessa; H Bouterfa; H Hameister; D Doenecke
Journal:  Mamm Genome       Date:  1995-08       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.